Serum qAnti‐HBc combined with ALT and HBsAg predicts significant hepatic inflammation in HBeAg‐positive immune active patients

Wang, Xiaomei; Gao, Xiuzhu; Wu, Ruihong; Chi, Xiumei; Xu, Hao; Guan, Yazhe; Jin, Qinglong; Niu, Junqi

doi:10.1111/jgh.15881

Cited by 5 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While some studies report that qAnti-HBc levels were helpful in the prediction of moderate-to-severe inflammation in both HBeAg-positive and HBeAg-negative CHB phases, others indicate that this benefit is more exhibited in HBe-positive patients [ 19 , 44 , 47 ]. Most authors emphasise that qAnti-HBc alone is not enough to predict the inflammation grade accurately and that its combination with other biomarkers is desirable [ 44 , 45 , 47 , 49 ]. There is a conclusion from a recent study that combined qAnti-HBc, ALT, and HBsAg offer better performance in predicting significant liver inflammation than qAnti-HBc alone or in combination with only ALT [ 49 ].…”

Section: Clinical Utility Of Qanti-hbcmentioning

confidence: 99%

“…Most authors emphasise that qAnti-HBc alone is not enough to predict the inflammation grade accurately and that its combination with other biomarkers is desirable [ 44 , 45 , 47 , 49 ]. There is a conclusion from a recent study that combined qAnti-HBc, ALT, and HBsAg offer better performance in predicting significant liver inflammation than qAnti-HBc alone or in combination with only ALT [ 49 ]. According to a recent study, following the worsening of inflammation and progression of fibrosis through phases of CHB, qAnti-HBc levels were increasing slowly but constantly from HBeAg-positive to HBeAg-negative phases.…”

Section: Clinical Utility Of Qanti-hbcmentioning

confidence: 99%

“…[ 21 , 37 , 39 , 40 ] (prediction of viral reactivation upon immunosuppression), refs. [ 19 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 ] (prediction of hepatic inflammation grade), refs. [ 50 , 51 , 52 , 53 ] (prediction of fibrosis stage), ref.…”

Section: Figurementioning

confidence: 99%

See 2 more Smart Citations

Clinical Utility of Quantitative HBV Core Antibodies for Solving Diagnostic Dilemmas

Lazarević

Banko

Miljanovic

et al. 2023

Viruses

View full text Add to dashboard Cite

The present-day management of hepatitis B virus (HBV) infection relies on constant and appropriate monitoring of viral activity, disease progression and treatment response. Traditional HBV infection biomarkers have many limitations in predicting clinical outcomes or therapy success. Quantitation of HBV core antibodies (qAnti-HBc) is a new non-invasive biomarker that can be used in solving multiple diagnostic problems. It was shown to correlate well with infection phases, level of hepatic inflammation and fibrosis, exacerbations during chronic infection and presence of occult infection. Further, the level of qAnti-HBc was recognised as predictive of spontaneous or therapy-induced HBeAg and HBsAg seroclearance, relapse after therapy discontinuation, re-infection after liver transplantation and viral reactivation upon immunosuppression. However, qAnti-HBc cannot be relied upon as a single diagnostic test to solve all dilemmas, and its diagnostic and prognostic power can be much improved when combined with other diagnostic biomarkers (HBV DNA, HBeAg, qHBsAg and anti-HBs antibodies). The availability of commercial qAnti-HBc diagnostic kits still needs to be improved. The comparison of results from different studies and definitions of universal cut-off values continue to be hindered because many methods are only semi-quantitative. The clinical utility of qAnti-HBc and the methods used for its measurement are the focus of this review.

show abstract

Section: Clinical Utility Of Qanti-hbcmentioning

confidence: 99%

Section: Clinical Utility Of Qanti-hbcmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Utility of Quantitative HBV Core Antibodies for Solving Diagnostic Dilemmas

Lazarević

Banko

Miljanovic

et al. 2023

Viruses

View full text Add to dashboard Cite

show abstract

“…Several studies noted the positive correlation between serum ALT activity and qAnti-HBc in CHB patients, suggesting the latter may indicate hepatic inflammation [ 26 , 27 , 28 ]. Moreover, qAnti-HBc has been documented to correlate positively with the histological severity of hepatic inflammation determined by liver biopsy [ 28 , 29 , 30 ]. Interestingly, some studies have found that qAnti-HBc is also associated with fibrosis severity and can provide improved value for the performance of non-invasive indexes in combination with other parameters [ 31 , 32 , 33 ].…”

Section: The Qanti-hbc Levels In the Natural History Of Hbv Infectionmentioning

confidence: 99%

Hepatitis B Core Antibody Level: A Surrogate Marker for Host Antiviral Immunity in Chronic Hepatitis B Virus Infections

Shi

Wang

et al. 2023

Viruses

View full text Add to dashboard Cite

The hepatitis B virus core protein (HBcAg) is a highly immunogenic particulate antigen. Nearly all patients with persistent or resolved hepatitis B virus (HBV) infection show seropositivity for hepatitis B core antibody (anti-HBc), which appears in the early stage of infection and is mostly present for life. Traditionally, the anti-HBc is regarded as an evidential serological marker of HBV infections. In the last ten years, several studies revealed the predictive value of quantitative anti-HBc (qAnti-HBc) level in the treatment response and clinical outcome of chronic HBV infections, implying new insights into this classic marker. Overall, qAnti-HBc should be regarded as an indicator of the host’s immune response specific to HBV, which correlates with HBV-related hepatitis activity and liver pathology. This review summarized the latest understanding of the clinical values of qAnti-HBc for differentiating the CHB phase, predicting treatment response, and providing disease prognosis. Moreover, we also discussed the possible mechanism of qAnti-HBc regulation during different courses of HBV infection.

show abstract

A novel model based on serum N‐glycan markers for evaluating stage of liver necroinflammation in treatment‐naïve chronic hepatitis B patients

Su,

Yan,

Jiang

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

This study aimed to establish a novel noninvasive model based on the serum N‐glycan spectrum for providing an objective value for determining the stage of liver necroinflammation related to chronic hepatitis B (CHB) patients. N‐glycan profiles of the sera of 295 treatment‐naïve CHB patients were analyzed. N‐glycan profiles were tested for different liver necroinflammation stages using DNA sequence‐assisted fluorophore‐assisted carbohydrate electrophoresis. A serum N‐glycan model named N‐glycan‐LI (NGLI) using support vector machine was selected to evaluate the classification of liver necroinflammation (G < 2 and G ≥ 2). The area under the receiver operating characteristic curves (AUROCs) was 0.898 (training set, n = 236) and 0.911 (validation set, n = 59) regardless of the stage of liver fibrosis (AUROC = 0.886 and 0.926, respectively, in S < 2 and S ≥ 2 group). The NGLI correspondingly had the highest specificity (SP) of 90.79% and negative predictive value of 92.00% in an inactive stage (including immune‐tolerant [IT] and inactive‐carrier [IC] stage), had the highest positive predictive value of 95.18% in stage immune‐active, and had the highest SP of 93.94% in grey zone IT + IC. N‐glycan profiles appear to correlate well with hepatic necroinflammation in CHB when compared with liver biopsy. The newly developed model appears to reliably predict liver damage in naïve‐treatment patients with CHB.

show abstract

Serum qAnti‐HBc combined with ALT and HBsAg predicts significant hepatic inflammation in HBeAg‐positive immune active patients

Abstract: Author contributions: Junqi Niu and Qinglong Jin designed and supervised the study. Xiaomei Wang analyzed the data and drafted the manuscript. Xiuzhu Gao, Xiumei Chi, and Yazhe Guan acquired the data. Ruihong Wu and Hongqin Xu performed the statistical analysis.

Cited by 5 publications

References 36 publications

Clinical Utility of Quantitative HBV Core Antibodies for Solving Diagnostic Dilemmas

Clinical Utility of Quantitative HBV Core Antibodies for Solving Diagnostic Dilemmas

Hepatitis B Core Antibody Level: A Surrogate Marker for Host Antiviral Immunity in Chronic Hepatitis B Virus Infections

A novel model based on serum N‐glycan markers for evaluating stage of liver necroinflammation in treatment‐naïve chronic hepatitis B patients

Contact Info

Product

Resources

About